Merck has stopped supplying Recarbrio in the United States, discontinuing an antibiotic the FDA approved seven years ago for patients with serious infections and few or no remaining treatment options. The company offered no explanation for the decision, which became public through drug-shortage tracking listings earlier this month.

Recarbrio is a three-drug combination injection of imipenem, cilastatin and relebactam. The FDA approved it for adults and children with hospital- or ventilator-associated pneumonia, complicated urinary tract infections and complicated stomach infections — indications reserved for patients with limited or no alternative therapies. That framing was deliberate. From the outset, the agency positioned Recarbrio as a treatment of last resort, an approach intended to mitigate the spread of antibiotic resistance by discouraging routine use of the drug.

The stewardship logic that protects the compound also caps its commercial ceiling. Restricting an antibiotic to last-resort status constrains prescriptions, volumes and, ultimately, revenue. Merck never broke out Recarbrio sales in its regulatory filings, a silence that itself signaled the product's marginal weight in the company's portfolio. Now the drug is gone from the U.S. supply chain entirely, and the company has not said whether manufacturing economics, supply-chain constraints or portfolio strategy drove the withdrawal.

For hospital pharmacies and infectious-disease teams, the practical question is immediate: which patients lose access, and what replaces the regimen. Recarbrio's indications cover some of the hardest-to-treat infections in inpatient care — ventilator pneumonia, complicated urinary tract and abdominal infections in patients who have run out of options. A discontinuation in this segment is not a routine product-line trim; it removes a tool designed precisely for resistance-heavy cases where alternatives are scarce.

The withdrawal also lands in a policy debate that has run for years: whether large pharmaceutical companies can sustain commitment to antibiotics, a category where public-health value and commercial incentive point in opposite directions. New antibiotics are deliberately held in reserve to slow resistance, which suppresses sales; the drugs that society most needs to keep on the shelf are the ones least likely to earn their development costs back. Recarbrio now stands as a concrete case of that tension resolving in favor of exit rather than endurance.

There are limits to what the available record shows. Merck has not disclosed the discontinuation's rationale, has not published Recarbrio revenue, and has not detailed the timeline of remaining supply or any planned reintroduction. Any assessment of the decision's drivers — manufacturing cost, low utilization, portfolio reallocation — remains inference until the company or regulators say more. What is documented is the fact of withdrawal itself and the FDA's original last-resort framing, which constrained the drug's market from approval onward.

The episode will feed into ongoing arguments over antibiotic incentives — subscription-style payment models, push funding, and public manufacturing options that supporters say could keep essential compounds available when private returns fall short. Merck's move, unexplained and quiet, gives those arguments a fresh and pointed example.

Whether Recarbrio returns to the U.S. market, or remains a discontinued case study in the economics of last-resort antibiotics, now depends on decisions Merck has yet to make public.